Dr. Ilya G. Glezerman, MD

Dr. Glezerman practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Glezerman's NPI, 1821069865, was assigned on January 29, 2006. Dr. Glezerman graduated from Albany Medical College in 1998. Dr. Glezerman holds New York license 215266.

Dr. Glezerman's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Glezerman's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Glezerman to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Glezerman practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Glezerman's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Glezerman is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Glezerman's licenses on file in 4 states: New York, Florida, Pennsylvania and New Jersey.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, gout and kidney cysts among the conditions Dr. Glezerman treats.

CMS data shows 498 Medicare services from Dr. Glezerman across 9 procedure codes in 2024, for 269 Medicare patients. Medicare paid $48,294 for them.

CMS counts 269 Medicare patients who saw Dr. Glezerman in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 3.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Glezerman's median patient age at 72, with 30% women.

In 2024, Dr. Glezerman wrote 257 Medicare Part D claims for 52 patients. 86% of them were for generic drugs. CMS names the drug for 84 of them, across 5 drugs with 11 or more claims each, at $5,648 in total drug cost. In 2023, CMS named 121 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Glezerman for performance year 2024, reported as part of a group. Dr. Glezerman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Glezerman as offering telehealth.

Dmand AI links 69 papers to Dr. Glezerman, published from 2003 to 2024. 2020 was the busiest year, with 12. The most frequent topics are Acute Kidney Injury, Immune Checkpoint Inhibitors and Immunotherapy. Dr. Glezerman has published most often in Support Care Cancer. Dr. Glezerman's most frequent co-authors are Ala Abudayyeh, MD, Kenar Dinesh Jhaveri, MD and Vickie R. Shannon, MD.

CMS Open Payments shows 1 general payment to Dr. Glezerman from 1 drug or device company in 2016. Consulting fees make up the largest share, 100% of the total. Amgen Inc. paid the most, $2,850.

Dr. Glezerman graduated from Albany Medical College in 1998.

Dr. Glezerman is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.